Mu42

We are a biopharmaceutical company dedicated to developing innovative solutions for pain management. Our focus is on the discovery and development of a novel, safer class of analgesics through the use of transmembrane allosteric modulation of the mu opioid receptor. Our goal is to bring a new level of safety and efficacy to patients suffering from chronic pain, reducing dependence and adverse effects associated with traditional opioids. With our cutting-edge research and dedication to improving patient lives, we aim to revolutionize the pain management industry.